
Conference Coverage
21 days ago
Elevate-Derm Summer Clinical Pearlsabout 1 month ago
GLP-1 Candidacy and Prescribing Considerations in PsoriasisLatest News

Q&A: Strategies for Protecting Skin in Winter, With Jeanine B. Downie, MD

Weighing Cross-Trial Data and Patient Timelines in Alopecia Areata Treatment

Q&A: Skin Cancer Prevention Beyond Summer, With Jill Cowan, APRN, FNP-BC

TanPrevent and the Case for Preventing Thousands of Melanomas

Bioelements and Celluma Collaborate on LED Facial Treatments
Videos

Shorts










Dermatology Times Digital Edition









All News

FDA implements updated iPLEDGE REMS requirements for isotretinoin, allowing at-home pregnancy testing and reducing prescription and counseling burdens.

Bosakitug failed to meet primary and secondary endpoints in a phase 2 atopic dermatitis trial despite evidence of TSLP target engagement.

Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.

Hypochlorous acid sprays are trending as a post-gym skin care essential, but can they actually prevent sweat-related breakouts?

Clinicians discuss how type 2 inflammation informs treatment decisions across AD, prurigo nodularis, CSU, and bullous pemphigoid.

A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.

At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.

Gaurav Singh, MD, MPH, FACMS, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.

A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.

Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.

Phase 2 AMETHYST findings show continued improvements in skin redness and clinician- and patient-reported outcomes with litifilimab.

Phase 2/3 data show sustained hair growth and favorable safety outcomes with oral VDPHL01 in men with androgenetic alopecia.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.























